[{"id":"d28ab8ee-6425-4b0d-a1f2-bb5b8d3abed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00522652","created_at":"2021-01-18T01:53:18.314Z","updated_at":"2024-07-02T16:37:10.679Z","phase":"Phase 1","brief_title":"Phase I Trial of PX-478","source_id_and_acronym":"NCT00522652","lead_sponsor":"Cascadian Therapeutics Inc.","biomarkers":" HIF1A","pipe":"","alterations":" ","tags":["HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PX-478"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 08/01/2007","start_date":" 08/01/2007","primary_txt":" Primary completion: 05/01/2010","primary_completion_date":" 05/01/2010","study_txt":" Completion: 05/01/2010","study_completion_date":" 05/01/2010","last_update_posted":"2018-05-17"}]